The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.5M data for 737K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

10 articles for S Nanthakumar


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2.EBI
Vertex Pharmaceuticals
Discovery and SAR of novel 4-thiazolyl-2-phenylaminopyrimidines as potent inhibitors of spleen tyrosine kinase (SYK).EBI
Vertex Pharmaceuticals
Discovery of Novel Allosteric HCV NS5B Inhibitors. 2. Lactam-Containing Thiophene Carboxylates.EBI
Vertex Pharmaceuticals
Discovery and Optimization of Pyrazole Amides as Inhibitors of ELOVL1.EBI
Vertex Pharmaceuticals
ROCK inhibitors 4: Structure-activity relationship studies of 7-azaindole-based rho kinase (ROCK) inhibitors.EBI
Vertex Pharmaceuticals
Discovery of Novel Thiophene-Based, Thumb Pocket 2 Allosteric Inhibitors of the Hepatitis C NS5B Polymerase with Improved Potency and Physicochemical Profiles.EBI
Vertex Pharmaceuticals
Fragment-Based Discovery of Dual JC Virus and BK Virus Helicase Inhibitors.EBI
Vertex Pharmaceuticals
ROCK inhibitors 3: Design, synthesis and structure-activity relationships of 7-azaindole-based Rho kinase (ROCK) inhibitors.EBI
Vertex Pharmaceuticals
Design and Synthesis of a Novel Series of Orally Bioavailable, CNS-Penetrant, Isoform Selective Phosphoinositide 3-Kinaseγ (PI3Kγ) Inhibitors with Potential for the Treatment of Multiple Sclerosis (MS).EBI
Vertex Pharmaceuticals
Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles.BDB
Wyeth Research